Hebert A, Thiboutot D, Gold LS, et al. - In this investigation involving 1,440 patients, researchers tested the effectiveness and safety of clascoterone cream, 1%, a novel topical androgen receptor inhibitor, in 2 phase 3 randomized clinical trials (CB-03-01/25 and CB-03-01/26). Study participants were randomized to treatment with clascoterone cream, 1%, or vehicle cream and applied nearly 1 g to the whole face twice daily for 12 weeks. According to findings, clascoterone cream, 1%, a novel topical androgen receptor inhibitor, appears to show a favorable safety profile and increased acne treatment effectiveness. Adverse effects with the use of the cream of clascoterone, 1%, were mainly mild and close to those with vehicle use.